Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763608 | 0.84 | TSHR (0.42) | ALDH1A1CYP3A4CYP1A2LMNATSHR | |
| SCHEMBL4987182 | 0.83 | PNMT (0.57) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL10079990 | 0.82 | ADRB2 (0.44) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL20847708 | 0.82 | CYP1A2 (0.41) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL27236092 | 0.80 | CFD (0.44) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL18190402 | 0.80 | CYP1A2 (0.40) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL10635042 | 0.79 | ALDH1A1 (0.44) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL6141168 | 0.78 | ADRB2 (0.42) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL8660409 | 0.77 | ALDH1A1 (0.49) | ALDH1A1ADRB2ADRB1CYP3A4CYP2D6 | |
| SCHEMBL9664891 | 0.77 | ALDH1A1 (0.62) | ALDH1A1ADRB2ADRB1CYP3A4NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561251-A | Modulators of TREX1 | 星座制药公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-110730776-A | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and their use | 拜耳股份公司 | 2020-01-24 | — | — | CN | disclosed |
| WO-2018189011-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | WO | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| CN-102917590-B | Tricyclic compound and the PBK inhibitor containing described compound | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-02-17 | — | — | CN | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| US-7985572-B2 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF SE (DE) | 2011-07-26 | — | — | US | disclosed |
| EP-1599584-B1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF SE (DE) | 2009-07-01 | — | — | EP | disclosed |
| CN-100445375-C | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AG (DE) | 2008-12-24 | — | — | CN | disclosed |
| US-20060259999-A1 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-16 | — | — | US | disclosed |
| CN-1753990-A | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AG (DE) | 2006-03-29 | — | — | CN | disclosed |
| EP-1599584-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076655-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-10 | — | — | WO | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | ALDH1A1 808/4885ADRB2 871/4885ADRB1 1289/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | ALDH1A1 808/4885ADRB2 871/4885ADRB1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.